Last reviewed · How we verify
Nifedipine cream topical application
Nifedipine is a calcium channel blocker that relaxes vascular smooth muscle and improves blood flow when applied topically to affected tissues.
Nifedipine is a calcium channel blocker that relaxes vascular smooth muscle and improves blood flow when applied topically to affected tissues. Used for Anal fissures (chronic pain and healing promotion), Raynaud's phenomenon (topical vasodilation).
At a glance
| Generic name | Nifedipine cream topical application |
|---|---|
| Sponsor | Western Galilee Hospital-Nahariya |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Nifedipine inhibits L-type calcium channels in vascular smooth muscle cells, reducing intracellular calcium and causing vasodilation. When formulated as a topical cream, it is applied locally to increase blood perfusion and reduce ischemic pain, particularly in conditions affecting peripheral blood vessels. The topical route allows direct local action while minimizing systemic exposure.
Approved indications
- Anal fissures (chronic pain and healing promotion)
- Raynaud's phenomenon (topical vasodilation)
Common side effects
- Local skin irritation or erythema
- Headache (from systemic absorption)
- Flushing
Key clinical trials
- Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease
- Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud (EARLY_PHASE1)
- Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: